Age-related Macular Degeneration Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 – 2032

Age-related Macular Degeneration Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 – 2032

The Global Age-related Macular Degeneration Market was valued at USD 10.4 billion in 2023 and is expected to grow at a CAGR of 9.8% from 2024 to 2032. AMD is a progressive eye condition that affects central vision due to damage to the macula, the part of the retina responsible for sharp and direct vision. This condition primarily impacts older adults, becoming increasingly prevalent as the global population ages.

The market is categorized by product into treatments such as Eylea, Lucentis, Beovu, Vabysmo, Syfovre, Avastin, and others. Eylea dominated the market in 2023, generating USD 4.4 billion in revenue. Its widespread adoption stems from proven clinical efficacy, consistent safety results, and the flexibility of monthly or bi-monthly dosing options. This adaptability improves patient compliance, which is essential for managing chronic conditions like AMD.

AMD is further classified by disease type into wet and dry AMD. Wet AMD, which accounted for USD 8.5 billion in revenue in 2023, represents the leading cause of vision impairment among older adults. This disease involves abnormal blood vessel growth beneath the retina, resulting in fluid leakage and central vision loss. Treatments targeting vascular endothelial growth factor (VEGF) are the primary intervention for controlling disease progression. The rising global aging population, coupled with increasing life expectancy, has led to a surge in wet AMD cases, intensifying the need for effective, vision-preserving therapies. Innovations addressing the burden of frequent injections are gaining traction, offering patients more convenient dosing schedules and improving treatment adherence.

Regionally, the U.S. market accounted for USD 4.2 billion in 2023 and is anticipated to grow at a CAGR of 9.9% during the forecast period. The increasing elderly population in the U.S. drives demand for advanced AMD treatment options. With a robust biopharmaceutical industry, the country is at the forefront of developing innovative AMD therapies, including gene therapies, extended-release drug formulations, and combination treatments. These advancements aim to provide more effective and accessible solutions for managing AMD as its prevalence continues to rise.